Investigation of aromatase inhibitory activity of metal complexes of 8-hydroxyquinolineand uracil derivatives

Drug Design, Development and Therapy

Volumn 8, Issue , 2014, Pages 1089-1096

  Prachayasittikul, Veda ^a   Pingaew, Ratchanok ^b   Nantasenamat, Chanin ^a   Prachayasittikul, Supaluk ^a   Ruchirawat, Somsak ^c,d   Prachayasittikul, Virapong ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b SRINAKHARINWIROT UNIVERSITY   (Thailand)

^c Toxicology and Management of Chemicals   (Thailand)

^d Research and Innovation   (Thailand)

Author keywords

Anticancer; Aromatase inhibitor; Metal based compound

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 5 NITROURACIL; 8 QUINOLINOL; AROMATASE; AROMATASE INHIBITOR; COPPER COMPLEX; DOXORUBICIN; IODOURACIL; KETOCONAZOLE; LETROZOLE; MANGANESE DERIVATIVE; METAL COMPLEX; NICKEL COMPLEX; UNCLASSIFIED DRUG; URACIL DERIVATIVE; COORDINATION COMPOUND; COPPER; MANGANESE; NICKEL; NITRILE; TRIAZOLE DERIVATIVE; URACIL;

ANALYTICAL EQUIPMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; DRUG CYTOTOXICITY; DRUG STRUCTURE; EMBRYO; ENZYME ASSAY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; LUNG ALVEOLUS CELL; STRUCTURE ANALYSIS; CELL LINE; CHEMISTRY; COMPARATIVE STUDY; CYTOLOGY; DRUG EFFECTS; IC50; LUNG;

AROMATASE INHIBITORS; CELL LINE; COORDINATION COMPLEXES; COPPER; HUMANS; INHIBITORY CONCENTRATION 50; KETOCONAZOLE; LUNG; MANGANESE; NICKEL; NITRILES; OXYQUINOLINE; TRIAZOLES; URACIL;

EID: 84906242390     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S67300     Document Type: Article

References (91)

1. Brueggemeier RW, Hackett JC, Diaz-Cruz ES. Aromatase inhibitors in the treatment of breast cancer. Endocr Rev. 2005;26(3):331-345.
2. Martín-Millán M, Castañeda S. Estrogens, osteoarthritis and inflammation. Joint Bone Spine. 2013;80(4):368-373.
3. Straub RH. The complex role of estrogens in inflammation. Endocr Rev. 2007;28(5):521-574.
4. Cutolo M, Wilder RL. Different roles for androgens and estrogens in the susceptibility to autoimmune rheumatic diseases. Rheum Dis Clin North Am. 2000;26(4):825-839.
5. Pettersson K, Gustafsson JA. Role of estrogen receptor beta in estrogen action. Annu Rev Physiol. 2001;63(1):165-192.
6. Michet CJ Jr, McKenna CH, Elveback LR, Kaslow RA, Kurland LT. Epidemiology of systemic lupus erythematosus and other connective tissue diseases in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc. 1985;60(2):105-113.
7. Couse JF, Korach KS. Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev. 1999;20(3):358-417.
8. Attar E, Bulun SE. Aromatase and other steroidogenic genes in endometriosis: translational aspects. Hum Reprod Update. 2006;12(1): 49-56.
9. Recanatini M, Cavalli A, Valenti P. Nonsteroidal aromatase inhibitors: recent advances. Med Res Rev. 2002;22(3):282-304.
10. Simpson ER, Mahendroo MS, Means GD, et al. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev. 1994;15(3):342-355.
11. Schweikert HU, Milewich L, Wilson JD. Aromatization of androstenedione by cultured human fibroblasts. J Clin Endocrinol Metab. 1976;43(4):785-795.
12. Perel E, Wilkins D, Killinger DW. The conversion of androstenedione to estrone, estradiol, and testosterone in breast tissue. J Steroid Biochem. 1980;13(1):89-94.
13. Miller WR, Hawkins RA, Forrest AP. Significance of aromatase activity in human breast cancer. Cancer Res. 1982;42(Suppl 8): 3365s-3368s.
14. Richelson LS, Wahner HW, Melton LJ, Riggs BL. Relative contributions of aging and estrogen deficiency to postmenopausal bone loss. N Engl J Med. 1984;311(20):1273-1275.
15. Osborne CK. Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat. 1998;51(3):227-238.
16. Simpson E, Rubin G, Clyne C, et al. The role of local estrogen biosynthesis in males and females. Trends Endocrinol Metab. 2000;11(5): 184-188.
17. Yang S, Fang Z, Suzuki T, et al. Regulation of aromatase P450 expression in endometriotic and endometrial stromal cells by CCAAT/enhancer binding proteins (C/EBPs): decreased C/EBPbeta in endometriosis is associated with overexpression of aromatase. J Clin Endocrinol Metab. 2002;87(5):2336-2345.
18. Yamaki J, Yamamoto T, Okada H. Aromatization of androstenedione by normal and neoplastic endometrium of the uterus. J Steroid Biochem. 1985;22(1):63-66.
19. Watanabe K, Sasano H, Harada N, et al. Aromatase in human endometrial carcinoma and hyperplasia. Immunohistochemical, in situ hybridization, and biochemical studies. Am J Pathol. 1995;146(2): 491-500.
20. Löfgren L, Wallberg B, Wilking N, et al. Tamoxifen and megestrol acetate for postmenopausal breast cancer: diverging effects on liver proteins, androgens, and glucocorticoids. Med Oncol. 2004;21(4):309-318.
21. Sainsbury R. The development of endocrine therapy for women with breast cancer. Cancer Treat Rev. 2013;39(5):507-517.
22. Brueggemeier RW, Li PK, Chen HH, Moh PP, Katlic NE. Biochemical and pharmacological development of steroidal inhibitors of aromatase. J Steroid Biochem Mol Biol. 1990;37(3):379-385.
23. Graves PE, Salhanick HA. Stereoselective inhibition of aromatase by enantiomers of aminoglutethimide. Endocrinology. 1979;105(1): 52-57.
24. Vanden Bossche H, Willemsens G, Roels I, et al. R 76713 and enantiomers: selective, nonsteroidal inhibitors of the cytochrome P450-dependent oestrogen synthesis. Biochem Pharmacol. 1990;40(8): 1707-1718.
25. Mason JI, Murry BA, Olcott M, Sheets JJ. Imidazole antimycotics: inhibitors of steroid aromatase. Biochem Pharmacol. 1985;34(7): 1087-1092.
26. Steele RE, Mellor LB, Sawyer WK, Wasvary JM, Browne LJ. In vitro and in vivo studies demonstrating potent and selective estrogen inhibition with the nonsteroidal aromatase inhibitor CGS 16949A. Steroids. 1987;50(1-3):147-161.
27. Bhatnagar AS, Häusler A, Schieweck K, Lang M, Bowman R. Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor. J Steroid Biochem Mol Biol. 1990;37(6): 1021-1027.
28. Albrecht M, Fiege M, Osetska O. 8-Hydroxyquinolines in metallosupramolecular chemistry. Coord Chem Rev. 2008;252(8-9):812-824.
29. Lescoat G, Léonce S, Pierré A, Gouffier L, Gaboriau F. Antiproliferative and iron chelating efficiency of the new bis-8-hydroxyquinoline benzylamine chelator S1 in hepatocyte cultures. Chem Biol Interact. 2012;195(2):165-172.
30. Prachayasittikul S, Worachartcheewan A, Pingaew R, et al. Metal complexes of uracil derivatives with cytotoxicity and superoxide scavenging activity. Lett Drug Des Discov. 2012;9(3):282-287.
31. Ding WQ, Lind SE. Metal ionophores - an emerging class of anticancer drugs. IUBMB Life. 2009;61(11):1013-1018.
32. Daniel KG, Chen D, Orlu S, Cui QC, Miller FR, Dou QP. Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells. Breast Cancer Res. 2005;7(6):R897-R908.
33. Prachayasittikul V, Prachayasittikul S, Ruchirawat S, Prachayasittikul V. 8-Hydroxyquinolines: a review of their metal chelating properties and medicinal applications. Drug Des Devel Ther. 2013;7:1157-1178.
34. Zheng H, Gal S, Weiner LM, et al. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J Neurochem. 2005;95(1):68-78.
35. Zheng H, Weiner LM, Bar-Am O, et al. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. Bioorg Med Chem. 2005;13(3):773-783.
36. Pavlov A, Takuchev N, Georgieva N. Drug design by regression analyses of newly synthesized derivatives of 8-quinolinol. Biotechnology & Biotechnological Equipment. 2012;26(1):164-169.
37. Jeon JH, Lee CH, Lee HS. Antimicrobial activities of 2-methyl-8-hydroxyquinoline and its derivatives against human intestinal bacteria. Journal of the Korean Society for Applied Biological Chemistry. 2009;52(2):202-205.
38. Ahmed SM, Ismail DA. Synthesis and biological activity of 8-hydroxyquinoline and 2-hydroxypyridine quaternary ammonium salts. J Surfactants Deterg. 2008;11(3):231-235.
39. Srisung S, Suksrichavalit T, Prachayasittikul S, Ruchirawat S, Prachayasittikul V. Antimicrobial activity of 8-hydroxyquinoline and transition metal complexes. International Journal of Pharmacology. 2013;9(2):170-175.
40. Strobl JS, Seibert CW, Li Y, et al. Inhibition of Toxoplasma gondii and Plasmodium falciparum infections in vitro by NSC3852, a redox active antiproliferative and tumor cell differentiation agent. J Parasitol. 2009;95(1):215-223.
41. Scheibel LW, Adler A. Antimalarial activity of selected aromatic chelators. III. 8-Hydroxyquinolines (oxines) substituted in positions 5 and 7, and oxines annelated in position 5,6 by an aromatic ring. Mol Pharmacol. 1982;22(1):140-144.
42. Madrid PB, Sherrill J, Liou AP, Weisman JL, Derisi JL, Guy RK. Synthesis of ring-substituted 4-aminoquinolines and evaluation of their antimalarial activities. Bioorg Med Chem Lett. 2005;15(4):1015-1018.
43. Kim YH, Woo KJ, Lim JH, et al. 8-Hydroxyquinoline inhibits iNOS expression and nitric oxide production by down-regulating LPS-induced activity of NF-kappaB and C/EBPbeta in Raw 264.7 cells. Biochem Biophys Res Commun. 2005;329(2):591-597.
44. Yamato M, Hashigaki K, Yasumoto Y, et al. Synthesis and antitumor activity of tropolone derivatives. 6. Structure-activity relationships of antitumor-active tropolone and 8-hydroxyquinoline derivatives. J Med Chem. 1987;30(10):1897-1900.
45. Álvarez P, Marchal JA, Boulaiz H, et al. 5-Fluorouracil derivatives: a patent review. Expert Opin Ther Pat. 2012;22(2):107-123.
46. Marchal JA, Boulaiz H, Rodríguez-Serrano F, et al. 5-fluorouracil derivatives induce differentiation mediated by tubulin and HLA class I modulation. Med Chem. 2007;3(3):233-239.
47. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003;21(1):92-98.
48. Adelstein DJ, Saxton JP, Lavertu P, et al. Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer with hyperfractionated radiation and concurrent chemotherapy. J Clin Oncol. 2002;20(5):1405-1410.
49. Moertel CG, Childs DS Jr, Reitemeier RJ, Colby MY Jr, Holbrook MA. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet. 1969;294(7626):865-867.
50. Seitz JF, Milan C, Giovannini M, et al; Fondation Française de Cancérologie Digestive; Groupe Digestif de la Fédération Nationale des Centres de Lutte Contre le Cancer. [Concurrent concentrated radio-chemotherapy of epidermoid cancer of the esophagus. Long-term results of a phase II national multicenter trial in 122 non-operable patients (FFCD 8803)]. Gastroenterol Clin Biol. 2000;24(2):201-210. French.
51. Saniger E, Campos JM, Entrena A, et al. Medium benzene-fused oxacycles with the 5-fluorouracil moiety: synthesis, antiproliferative activities and apoptosis induction in breast cancer cells. Tetrahedron. 2003;59(29):5457-5467.
52. Espinosa A, Marchal JA, Aránega A, Gallo MA, Aiello S, Campos J. Antitumoural properties of benzannelated seven-membered 5-fluorouracil derivatives and related open analogues. Molecular markers for apoptosis and cell cycle dysregulation. Farmaco. 2005;60(2):91-97.
53. Saniger E, Campos JM, Entrena A, et al. Neighbouring-group participation as the key step in the reactivity of acyclic and cyclic salicyl-derived O,O-acetals with 5-fluorouracil. Antiproliferative activity, cell cycle dysregulation and apoptotic induction of new O,N-acetals against breast cancer cells. Tetrahedron. 2003;59(40):8017-8026.
54. Mazzaferro S, Bouchemal K, Ponchel G. Oral delivery of anticancer drugs II: the prodrug strategy. Drug Discov Today. 2013;18(1-2):93-98.
55. Rafique S, Idrees M, Nasim A, Akbar H, Athar A. Transition metal complexes as potential therapeutic agents. Biotechnology and Molecular Biology Reviews. 2010;5(2):38-45.
56. Jackson A, Davis J, Pither RJ, Rodger A, Hannon MJ. Estrogen-derived steroidal metal complexes: agents for cellular delivery of metal centers to estrogen receptor-positive cells. Inorg Chem. 2001;40(16): 3964-3973.
57. Brow JM, Pleatman CR, Bierbach U. Cytotoxic acridinylthiourea and its platinum conjugate produce enzyme-mediated DNA strand breaks. Bioorg Med Chem Lett. 2002;12(20):2953-2955.
58. Hambley TW. Developing new metal-based therapeutics: challenges and opportunities. Dalton Trans. 2007;(43):4929-4937.
59. Suksrichavalit T, Prachayasittikul S, Nantasenamat C, Isarankura-Na-Ayudhya C, Prachayasittikul V. Copper complexes of pyridine derivatives with superoxide scavenging and antimicrobial activities. Eur J Med Chem. 2009;44(8):3259-3265.
60. Suksrichavalit T, Prachayasittikul S, Piacham T, Isarankura-Na-Ayudhya C, Nantasenamat C, Prachayasittikul V. Copper complexes of nicotinic-aromatic carboxylic acids as superoxide dismutase mimetics. Molecules. 2008;13(12):3040-3056.
61. Pingaew R, Worachartcheewan A, Prachayasittikul V, Prachayasittikul S, Ruchirawat S, Prachayasittikul V. Transition metal complexes of 8aminoquinoline-5-substituted uracils with antioxidative and cytotoxic activities. Lett Drug Des Discov. 2013;10(9):859-864.
62. Castonguay A, Doucet C, Juhas M, Maysinger D. New ruthenium(II)-letrozole complexes as anticancer therapeutics. J Med Chem. 2012;55(20):8799-8806.
63. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1-2):55-63.
64. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 1987;47(4): 936-942.
65. Tominaga H, Ishiyama M, Ohseto F, et al. A water-soluble tetrazolium salt useful for colorimetric cell viability assay. Analytical Communications. 1999;36(2):47-50.
66. Stresser DM, Turner SD, McNamara J, et al. A High-throughput screen to identify inhibitors of aromatase (CYP19). Anal Biochem. 2000;284(2):427-430.
67. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71-96.
68. Bulun SE, Noble LS, Takayama K, et al. Endocrine disorders associated with inappropriately high aromatase expression. J Steroid Biochem Mol Biol. 1997;61(3-6):133-139.
69. Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010;28(3):509-518.
70. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the international letrozole breast cancer group. J Clin Oncol. 2001;19(10): 2596-2606.
71. Paridaens RJ, Dirix LY, Beex LV, et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol. 2008;26(30):4883-4890.
72. Shippen ER, West WJ Jr. Successful treatment of severe endometriosis in two premenopausal women with an aromatase inhibitor. Fertil Steril. 2004;81(5):1395-1398.
73. Takayama K, Zeitoun K, Gunby RT, Sasano H, Carr BR, Bulun SE. Treatment of severe postmenopausal endometriosis with an aromatase inhibitor. Fertil Steril. 1998;69(4):709-713.
74. Amsterdam LL, Gentry W, Jobanputra S, Wolf M, Rubin SD, Bulun SE. Anastrazole and oral contraceptives: a novel treatment for endometriosis. Fertil Steril. 2005;84(2):300-304.
75. Brewer GJ. Copper control as an antiangiogenic anticancer therapy: lessons from treating Wilson's disease. Exp Biol Med (Maywood). 2001;226(7):665-673.
76. Theophanides T, Anastassopoulou J. Copper and carcinogenesis. Crit Rev Oncol Hematol. 2002;42(1):57-64.
77. Daniel KG, Harbach RH, Guida WC, Dou QP. Copper storage diseases: Menkes, Wilsons, and cancer. Front Biosci. 2004;9:2652-2662.
78. Nayak SB, Bhat VR, Upadhyay D, Udupa SL. Copper and ceruloplasmin status in serum of prostate and colon cancer patients. Indian J Physiol Pharmacol. 2003;47(1):108-110.
79. Huang YL, Sheu JY, Lin TH. Association between oxidative stress and changes of trace elements in patients with breast cancer. Clin Biochem. 1999;32(2):131-136.
80. Rizk SL, Sky-Peck HH. Comparison between concentrations of trace elements in normal and neoplastic human breast tissue. Cancer Res. 1984;44(11):5390-5394.
81. Turecký L, Kalina P, Uhlíková E, Námerová S, Križko J. Serum ceruloplasmin and copper levels in patients with primary brain tumors. Klin Wochenschr. 1984;62(4):187-189.
82. Chen D, Cui QC, Yang H, et al. Clioquinol, a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts. Cancer Res. 2007;67(4): 1636-1644.
83. Bleackley MR, Macgillivray RTA. Transition metal homeostasis: from yeast to human disease. Biometals. 2011;24(5):785-809.
84. Anjaneyulu Y, Rao RP, Swamy RY, Eknath A, Rao KN. In vitro antimicrobial-activity studies on the mixed ligand complexes of Hg(II) with 8-hydroxyquinoline and salicylic acids. Proceedings of the Indian Academy of Sciences - Chemical Sciences. 1982;91(2):157-163.
85. Pollak Y, Mechlovich D, Amit T, et al. Effects of novel neuroprotective and neurorestorative multifunctional drugs on iron chelation and glucose metabolism. J Neural Transm. 2013;120(1):37-48.
86. Crouch PJ, Barnham KJ. Therapeutic redistribution of metal ions to treat Alzheimer's disease. Acc Chem Res. 2012;45(9):1604-1611.
87. Cherny RA, Atwood CS, Xilinas ME, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron. 2001;30(3):665-676.
88. Bush AI, Tanzi RE. Therapeutics for Alzheimer's disease based on the metal hypothesis. Neurotherapeutics. 2008;5(3):421-432.
89. Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (Capecitabine, UFT, S-1): a review. Oncologist. 2002;7(4):288-323.
90. Ding WQ, Liu B, Vaught JL, Yamauchi H, Lind SE. Anticancer activity of the antibiotic clioquinol. Cancer Res. 2005;65(8):3389-3395.
91. Shaw AY, Chang CY, Hsu MY, et al. Synthesis and structure-activity relationship study of 8-hydroxyquinoline-derived Mannich bases as anticancer agents. Eur J Med Chem. 2010;45(7):2860-2867.